Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel von Lin, Z.P, Rutherford, T.J, Ratner, E.S

Volltext

Sexual function among older female cancer survivors von Patel, D, Erekson, E, Ratner, E.S

Volltext

MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy von Lin, Z.P, Sartorelli, A.C, Ratner, E.S

Volltext

A single institution’s experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions von Altwerger, G, Gressel, G.M, English, D.P, Nelson, W.K, Menderes, G, Black, J.D, Santin, A, Schwartz, P.E, Ratner, E.S

Volltext

Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme BRCA von Altwerger, G, Gressel, G.M, Menderes, G, Black, J.D, Nelson, W.K, Litkouhi, B, Santin, A, Schwartz, P.E, Ratner, E.S

Volltext

Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo von Menderes, G, Bonazzoli, E, Bellone, S, Black, J.D, Pettinella, F, Masserdotti, A, Zammataro, L, Lopez, S, Litkouhi, B, Ratner, E.S, Silasi, D.A, Azodi, M, Schwartz, P.E, Santin, A

Volltext

Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome von Jorgensen, E, Azodi, M, Ratner, E.S, Rutherford, T.J, Santin, A, Schwartz, P.E, Silasi, D.A

Volltext

Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo von Schwab, C.L, Roque, D.M, Bellone, S, Ratner, E.S, Silasi, D.A, Azodi, M, Schwartz, P.E, Rutherford, T.J, Santin, A

Volltext

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience von Schwab, C.L, English, D.P, Ratner, E.S, Silasi, D.A, Azodi, M, Rutherford, T.J, Schwartz, P.E, Santin, A

Volltext

Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma von Black, J.D, Lopez, S, Bellone, S, Schwab, C.L, English, D.P, Roque, D.M, Silasi, D.A, Ratner, E.S, Azodi, M, Rutherford, T.J, Schwartz, P.E, Santin, A

Volltext

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo von English, D.P, Black, J.D, Lopez, S, Bellone, S, Roque, D.M, Ratner, E.S, Silasi, D.A, Azodi, M, Rutherford, T.J, Schwartz, P.E, Santin, A

Volltext

Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and interval debulking von Roque, D.M, Schwab, C.L, Goloubeva, O, English, D.P, Black, J.D, Silasi, D.A, Azodi, M, Rutherford, T.J, Santin, A, Schwartz, P.E, Ratner, E.S

Volltext

Up-regulation of STAT3 signaling promotes invasion and metastasis of -mutated epithelial ovarian cancer von Lin, Z.P., Zhu, Y.L., Lo, Y.C., Huang, P.H., Ratner, E.S.

Volltext

Up-regulation of STAT3 signaling promotes invasion and metastasis of BRCA2-mutated epithelial ovarian cancer von Lin, Z.P., Zhu, Y.L., Lo, Y.C., Huang, P.H., Ratner, E.S.

Volltext

Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer von Lin, Z.P., Zhu, Y.L., Huang, P.H., Ratner, E.S.

Volltext

Impact of choice of chemotherapy on survival of patients with carcinosarcoma of the ovary: A retrospective review across two academic institutions von Haunschild, C., Altwerger, G., Ratner, E.S., English, D.P.

Volltext

Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cells von Alexandre, M., Lin, Z.P., Hanna, R.E., Ratner, E.S.

Volltext

The role of AKT and NHEJ pathways in the sensitivity of BRCA2-mutated epithelial ovarian cancer to PARP inhibitors von Xiong, A., Gokyer, D., Shapiro-Franklin, N., Lin, Z.P., Ratner, E.S.

Volltext

Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study von Webster, E.M., Dugan, K.B., McNamara, B., Lu, L., Azodi, M., Ratner, E.S., Schwartz, P.E., Menderes, G.

Volltext

Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer von Dugan, K.B., McNamara, B., Lu, L., Litkouhi, B., Azodi, M., Schwartz, P.E., Ratner, E.S., Menderes, G., Silasi, D.A.

Volltext